BioBrief covers three high-signal biopharma developments from Friday, May 1, 2026. The FDA approved the first targeted protein degrader drug, Revolution Medicines moved closer to access in pancreatic cancer, and Incyte added a once-daily formulation to defend the Jakafi franchise.

1. Arvinas / Pfizer — Veppanu
   • Mechanism: Oral estrogen receptor PROTAC / targeted protein degrader
   • Indication: ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
   • Stage: FDA approval
   • Key result: Median progression-free survival of 5.0 months versus 2.1 months for fulvestrant in 270 ESR1-mutated patients
   • Why it matters: First FDA-approved PROTAC, validating targeted protein degradation while raising launch questions in a narrow breast cancer label
2. Revolutio ...